MedPath

Comparing improvement efficacy of leishmaniasis patients with three treatment methods including combined cryotherapy and interalesional meglumine antimoniate (Glucantime) vs. cryotherapy and interalesional glucantime alone for the treatment of cutaneous leishmaniasis

Phase 2
Conditions
Cutaneous Leishmaniasis.
Cutaneous Leishmaniasis
Registration Number
IRCT138903063862N4
Lead Sponsor
Research Council of Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
180
Inclusion Criteria

presence of cutaneous leishmaniasis less than 6 months that their disease has been approved by direct smear and stained with Giemsa or positive skin biopsy, a 3-month treatment free interval from the last treatment course. Exclusion criteria: pregnancy, lactating, receiving simultaneously any therapy during study period that has antileishmaniasis effect during 2 months ago, history of significant renal, pulmonary and cardiovascular disease.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete healing. Timepoint: For the first time 6th and 8th weeks after treatment and for the second time in follow up visit after 3 months of beginning the study. Method of measurement: Measuring the size of induration and ulcer.
Secondary Outcome Measures
NameTimeMethod
Side effects. Timepoint: at each follow up visit. Method of measurement: Physical exam.
© Copyright 2025. All Rights Reserved by MedPath